<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25502522</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-660X</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical microbiology</Title><ISOAbbreviation>J Clin Microbiol</ISOAbbreviation></Journal><ArticleTitle>Nonstructural protein 1-specific immunoglobulin M and G antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>566</EndPage><MedlinePgn>557-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JCM.02735-14</ELocationID><Abstract><AbstractText>IgM antibody- and IgG antibody-capture enzyme-linked immunosorbent assays (MAC/GAC-ELISAs) targeted at envelope protein (E) of dengue viruses (DENV), West Nile virus, and Japanese encephalitis virus (JEV) are widely used as serodiagnostic tests for presumptive confirmation of viral infection. Antibodies directed against the flavivirus nonstructural protein 1 (NS1) have been proposed as serological markers of natural infections among vaccinated populations. The aim of the current study is to optimize an IgM and IgG antibody-capture ELISA (MAC/GAC-ELISA) to detect anti-NS1 antibodies and compare it with anti-E MAC/GAC-ELISA. Plasmids to express premembrane/envelope (prM/E) or NS1 proteins of six medically important flaviviruses, including dengue viruses (DENV-1 to DENV-4), West Nile virus (WNV), and Japanese encephalitis virus (JEV), were constructed. These plasmids were used for the production of prM/E-containing virus-like particles (VLPs) and secreted NS1 (sNS1) from COS-1 cells. Archived clinical specimens from patients with confirmed DENV, JEV, and WNV infections, along with naive sera, were subjected to NS1-MAC/GAC-ELISAs before or after depletion of anti-prM/E antibodies by preabsorption with or without VLPs. Human serum specimens from previously confirmed DENV infections showed significantly enhanced positive-to-negative (P/N) ratios for NS1-MAC/GAC-ELISAs after the depletion of anti-prM/E antibodies. No statistical differences in sensitivities and specificities were found between the newly developed NS1- and VLP-MAC/GAC-ELISAs. Further application of the assays to WNV- and JEV-infected serum panels showed similar results. A novel approach to perform MAC/GAC-ELISAs for NS1 antibody detection was successfully developed with great potential to differentiate antibodies elicited by the tetravalent chimeric yellow fever-17D/dengue vaccine or DENV infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Day-Yu</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung-Hsing University, Taichung, Taiwan dychao@nchu.edu.tw gxc7@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galula</LastName><ForeName>Jedhan Ucat</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, College of Veterinary Medicine, National Chung-Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Wen-Fan</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Ph.D. Program in Microbial Genomics, National Chung-Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Brent S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA dychao@nchu.edu.tw gxc7@cdc.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Microbiol</MedlineTA><NlmUniqueID>7505564</NlmUniqueID><ISSNLinking>0095-1137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C100315">NS1 protein, Flavivirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018177" MajorTopicYN="N">Flavivirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25502522</ArticleId><ArticleId IdType="pmc">PMC4298564</ArticleId><ArticleId IdType="doi">10.1128/JCM.02735-14</ArticleId><ArticleId IdType="pii">JCM.02735-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lindenbach BD, Rice CM. 2001. Flaviviridae: the viruses and their replication, p 991&#x2013;1110. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 4th ed. Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Gubler DJ. 1998. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11:480&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M, Halstead S, Artsob H, Buchy P, Farrar J, Gubler D, Hunsperger E, Kroeger A, Margolis H, Mart&#xed;nez E, Nathan M, Pelegrino J, Simmons C, Yoksan S, Peeling R. 2010. Dengue: a continuing global threat. Nat Rev Microbiol 8:S7&#x2013;S16. doi:10.1038/nrmicro2460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2460</ArticleId><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. 2007. Dengue. Lancet 370:1644&#x2013;1652. doi:10.1016/S0140-6736(07)61687-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61687-0</ArticleId><ArticleId IdType="pubmed">17993365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle J, Harris E. 2008. Global spread and persistence of dengue. Annu Rev Microbiol 62:71&#x2013;92. doi:10.1146/annurev.micro.62.081307.163005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.62.081307.163005</ArticleId><ArticleId IdType="pubmed">18429680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C, Drake J, Brownstein J, Hoen A, Sankoh O, Myers M, George D, Jaenisch T, Wint G, Simmons C, Scott T, Farrar J, Hay S. 2013. The global distribution and burden of dengue. Nature 496:504&#x2013;507. doi:10.1038/nature12060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M, Luong C, Rusmil K, Wirawan D, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon I, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel T, Tornieporth N, Saville M, Bouckenooghe A, CYD14 Study Group . 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358&#x2013;1365. doi:10.1016/S0140-6736(14)61060-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61060-6</ArticleId><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu P, Huang J. 2004. Current advances in dengue diagnosis. Clin Diagn Lab Immunol 11:642&#x2013;650. doi:10.1128/CDLI.11.4.642-650.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.11.4.642-650.2004</ArticleId><ArticleId IdType="pmc">PMC440621</ArticleId><ArticleId IdType="pubmed">15242935</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Kitai Y. 2009. Detection by ELISA of antibodies to Japanese encephalitis virus nonstructural 1 protein induced in subclinical infected humans. Vaccine 27:7053&#x2013;7058. doi:10.1016/j.vaccine.2009.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.09.064</ArticleId><ArticleId IdType="pubmed">19786140</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Shoda M, Ajiro N, Kondo T. 2004. Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses. J Clin Microbiol 42:5087&#x2013;5093. doi:10.1128/JCM.42.11.5087-5093.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.11.5087-5093.2004</ArticleId><ArticleId IdType="pmc">PMC525176</ArticleId><ArticleId IdType="pubmed">15528700</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Suzuki T. 2002. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21:98&#x2013;107. doi:10.1016/S0264-410X(02)00433-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00433-4</ArticleId><ArticleId IdType="pubmed">12443667</ArticleId></ArticleIdList></Reference><Reference><Citation>Namekar M, Ellis E, O'Connell M, Elm J, Gurary A, Park S, Imrie A, Nerurkar V. 2013. Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of dengue virus infection. J Clin Microbiol 51:3102&#x2013;3106. doi:10.1128/JCM.00351-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00351-13</ArticleId><ArticleId IdType="pmc">PMC3754626</ArticleId><ArticleId IdType="pubmed">23824771</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch R, Chang G, Litwin C. 2014. Comparison of a commercial dengue IgM capture ELISA with dengue antigen focus reduction microneutralization test and the Centers for Disease Control dengue IgM capture-ELISA. J Virol Methods 195:247&#x2013;249. doi:10.1016/j.jviromet.2013.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.10.019</ArticleId><ArticleId IdType="pubmed">24161816</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacksell S, Jarman R, Gibbons R, Tanganuchitcharnchai A, Mammen MJ, Nisalak A, Kalayanarooj S, Bailey M, Premaratna R, de Silva H, Day N, Lalloo D. 2012. Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin Vaccine Immunol 19:804&#x2013;810. doi:10.1128/CVI.05717-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05717-11</ArticleId><ArticleId IdType="pmc">PMC3346317</ArticleId><ArticleId IdType="pubmed">22441389</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G, Davis B, Stringfield C, Lutz C. 2007. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection. Vaccine 25:2325&#x2013;2330. doi:10.1016/j.vaccine.2006.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.11.056</ArticleId><ArticleId IdType="pubmed">17224209</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G, Hunt A, Holmes D, Springfield T, Chiueh T, Roehrig J, Gubler D. 2003. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306:170&#x2013;180. doi:10.1016/S0042-6822(02)00028-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0042-6822(02)00028-4</ArticleId><ArticleId IdType="pubmed">12620809</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill W, Hughes H, Delorey M, Chang G. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991. doi:10.1371/journal.pone.0004991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes D, Purdy D, Chao D, Noga A, Chang G. 2005. Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections. J Clin Microbiol 43:3227&#x2013;3236. doi:10.1128/JCM.43.7.3227-3236.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.7.3227-3236.2005</ArticleId><ArticleId IdType="pmc">PMC1169144</ArticleId><ArticleId IdType="pubmed">16000440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou S, Crill W, Chen L, Chang G. 2008. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol 15:825&#x2013;835. doi:10.1128/CVI.00004-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00004-08</ArticleId><ArticleId IdType="pmc">PMC2394851</ArticleId><ArticleId IdType="pubmed">18337381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewthwaite P, Shankar M, Tio P, Daly J, Last A, Ravikumar R, Desai A, Ravi V, Cardosa J, Solomon T. 2010. Evaluation of two commercially available ELISAs for the diagnosis of Japanese encephalitis applied to field samples. Trop Med Int Health 15:811&#x2013;818. doi:10.1111/j.1365-3156.2010.02537.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3156.2010.02537.x</ArticleId><ArticleId IdType="pubmed">20487425</ArticleId></ArticleIdList></Reference><Reference><Citation>Akey D, Brown W, Dutta S, Konwerski J, Jose J, Jurkiw T, DelProposto J, Ogata C, Skiniotis G, Kuhn R, Smith J. 2014. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science 343:881&#x2013;885. doi:10.1126/science.1247749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1247749</ArticleId><ArticleId IdType="pmc">PMC4263348</ArticleId><ArticleId IdType="pubmed">24505133</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcon-LePoder S, Sivard P, Drouet M, Talarmin A, Rice C, Flamand M. 2006. Secretion of flaviviral non-structural protein NS1: from diagnosis to pathogenesis. Novartis Found Symp 277:233&#x2013;247. doi:10.1002/0470058005.ch17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0470058005.ch17</ArticleId><ArticleId IdType="pubmed">17319166</ArticleId></ArticleIdList></Reference><Reference><Citation>Flamand M, Megret F, Mathieu M, Lepault J, Rey F, Deubel V. 1999. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol 73:6104&#x2013;6110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112675</ArticleId><ArticleId IdType="pubmed">10364366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason P. 1989. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 169:354&#x2013;364. doi:10.1016/0042-6822(89)90161-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(89)90161-X</ArticleId><ArticleId IdType="pmc">PMC7125691</ArticleId><ArticleId IdType="pubmed">2523178</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlesinger J, Brandriss M, Cropp C, Monath T. 1986. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol 60:1153&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253373</ArticleId><ArticleId IdType="pubmed">3783816</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlesinger J, Brandriss M, Walsh E. 1987. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 68:853&#x2013;857. doi:10.1099/0022-1317-68-3-853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-68-3-853</ArticleId><ArticleId IdType="pubmed">3819700</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Bray M, Schlesinger J, Lai C. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 64:4356&#x2013;4363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247903</ArticleId><ArticleId IdType="pubmed">2143542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung K, Nybakken G, Thompson B, Engle M, Marri A, Fremont D, Diamond M. 2006. Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80:1340&#x2013;1351. doi:10.1128/JVI.80.3.1340-1351.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.3.1340-1351.2006</ArticleId><ArticleId IdType="pmc">PMC1346945</ArticleId><ArticleId IdType="pubmed">16415011</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu P, Chen L, Chang S, Yueh Y, Chow L, Chien L, Chin C, Lin T, Huang J. 2001. Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination. Vaccine 19:1753&#x2013;1763. doi:10.1016/S0264-410X(00)00391-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00391-1</ArticleId><ArticleId IdType="pubmed">11166901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitai Y, Kondo T, Konishi E. 2010. Complement-dependent cytotoxicity assay for differentiating West Nile virus from Japanese encephalitis virus infections in horses. Clin Vaccine Immunol 17:875&#x2013;878. doi:10.1128/CVI.00217-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00217-09</ArticleId><ArticleId IdType="pmc">PMC2863385</ArticleId><ArticleId IdType="pubmed">20237201</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Kitai Y, Kondo T. 2008. Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus. Clin Vaccine Immunol 15:88&#x2013;94. doi:10.1128/CVI.00347-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00347-07</ArticleId><ArticleId IdType="pmc">PMC2223849</ArticleId><ArticleId IdType="pubmed">18032598</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira N, Broom A, Mackenzie J, Smith D, Lindsay M, Kay B, Hall R. 2006. Epitope-blocking enzyme-linked immunosorbent assay for detection of antibodies to Ross River virus in vertebrate sera. Clin Vaccine Immunol 13:814&#x2013;817. doi:10.1128/CVI.00035-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00035-06</ArticleId><ArticleId IdType="pmc">PMC1489576</ArticleId><ArticleId IdType="pubmed">16829622</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, Chien LJ, Chin C, Lin TH, Huang JH. 2003. Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 10:622&#x2013;630. doi:10.1128/CDLI.10.4.622-630.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.10.4.622-630.2003</ArticleId><ArticleId IdType="pmc">PMC164246</ArticleId><ArticleId IdType="pubmed">12853395</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu PY, Chen LK, Chang SF, Su CL, Chien LJ, Chin C, Lin TH, Huang JH. 2004. Dengue virus serotyping based on envelope and membrane and nonstructural protein NS1 serotype-specific capture immunoglobulin M enzyme-linked immunosorbent assays. J Clin Microbiol 42:2489&#x2013;2494. doi:10.1128/JCM.42.6.2489-2494.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.6.2489-2494.2004</ArticleId><ArticleId IdType="pmc">PMC427809</ArticleId><ArticleId IdType="pubmed">15184425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno G. 2003. Serodiagnosis of flaviviral infections and vaccinations in humans. Adv Virus Res 61:3&#x2013;65. doi:10.1016/S0065-3527(03)61001-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-3527(03)61001-8</ArticleId><ArticleId IdType="pubmed">14714429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome: organization, expression and replication. Annu Rev Microbiol 44:649&#x2013;688. doi:10.1146/annurev.mi.44.100190.003245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>